Volume 27, Number 11—November 2021
Research
Genomic Profiling of Mycobacterium tuberculosis Strains, Myanmar
Figure 1
![Genomic profiling of Mycobacterium tuberculosis strains, Myanmar, comparing discriminatory power offered by GeneXpert (Cepheid, https://www.cepheid.com) and additional genotypic testing, such as line-probe assay or whole-genome sequencing. RIF resistance and sensitivity were determined by using the Xpert MTB/RIF assay (Cepheid). INH, isoniazid; MDR, multidrug resistant; RIF, rifampin; RR, rifampin resistant; RS rifampin sensitive; XDR, extensively drug resistant. *Resistance profile confirmed by phenotypic testing.](/eid/images/21-0726-F1.jpg)
Figure 1. Genomic profiling of Mycobacterium tuberculosis strains, Myanmar, comparing discriminatory power offered by GeneXpert (Cepheid, https://www.cepheid.com) and additional genotypic testing, such as line-probe assay or whole-genome sequencing. RIF resistance and sensitivity were determined by using the Xpert MTB/RIF assay (Cepheid). INH, isoniazid; MDR, multidrug resistant; RIF, rifampin; RR, rifampin resistant; RS rifampin sensitive; XDR, extensively drug resistant. *Resistance profile confirmed by phenotypic testing.
1These authors contributed equally to this article.
Page created: July 13, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.